{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T06:37:04Z","timestamp":1790318224395,"version":"4.1.0"},"reference-count":16,"publisher":"BMJ","issue":"3","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Emerg Med J"],"accepted":{"date-parts":[[2024,1,11]]},"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Andexanet alfa was approved in 2018 for reversal of direct oral anticoagulants but due to issues of cost and access, four-factor prothrombin complex concentrate (4F-PCC) continues to be used for this indication. The objective of this study is to evaluate outcomes of reversal with these agents in patients with isolated traumatic brain injuries (TBI).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a retrospective review of 35 trauma centres from 2014 to 2021. Patients were included with an Abbreviated Injury Scale (AIS)&gt;2 for head and having received andexanet alfa or 4F-PCC within 24 hours of admission. Patients were excluded if P2Y12 inhibitor use or AIS&gt;2 outside of head. Primary outcome includes rate of mortality\/hospice at hospital discharge. Secondary outcomes include a composite of serious hospital complications. A subgroup analysis of severe TBI patients (AIS head 4 or 5) was completed. Multivariable logistic regression was used to account for differences in comorbidities and TBI severity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>4F-PCC was given to 265 patients with another 59 receiving andexanet alfa. Patients in the andexanet alfa group were more likely to have an AIS head score of 5 (47.5% vs 26.1%; p&lt;0.005). After adjusting for severity of TBI and comorbidities with regard to mortality\/hospice, there were 15 (25.4%) patients in the andexanet alfa group and 49 (18.5%) in the 4F-PCC group (OR 1.34; 95%\u2009CI 0.67 to 2.71). This remained consistent when looking at severe TBI patients with 12 (28.6%) andexanet alfa patients and 37 (28.7%) 4F-PCC patients (OR 0.93 (95% CI 0.40 to 2.16)). Severe hospital complications were also similar between groups with 5 (8.5%) andexanet alfa patients as compared with 21 (7.9%) 4F-PCC patients (OR 1.01; 95%\u2009CI 0.36 to 2.88).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>There was no firm conclusion on the treatment effect in mortality\/hospice or serious complications among isolated TBI patients reversed with 4F-PCC as compared with andexanet alfa.<\/jats:p><\/jats:sec>","DOI":"10.1136\/emermed-2023-213229","type":"journal-article","created":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T18:20:14Z","timestamp":1706120414000},"page":"162-167","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Four-factor prothrombin complex concentrate versus andexanet alfa for the reversal of traumatic brain injuries"],"prefix":"10.1136","volume":"41","author":[{"given":"Erin","family":"Sadek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Curtiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2853-3162","authenticated-orcid":false,"given":"Jason","family":"Hecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,1,24]]},"reference":[{"key":"2025062323251232000_41.3.162.1","unstructured":"CDC . Keep on your feet. Centers for Disease Control and Prevention, 2023."},{"key":"2025062323251232000_41.3.162.2","unstructured":"CDC Injury Center . Get the facts about TBI| concussion | traumatic brain injury. 2023."},{"key":"2025062323251232000_41.3.162.3","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.116.013343"},{"key":"2025062323251232000_41.3.162.4","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s12028-019-00866-6","article-title":"Key points to consider when evaluating Andexxa for Formulary addition","volume":"33","author":"Peled","year":"2020","journal-title":"Neurocrit Care"},{"key":"2025062323251232000_41.3.162.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.04.053"},{"key":"2025062323251232000_41.3.162.6","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s12028-020-01161-5","article-title":"Andexanet Alfa versus 4-factor prothrombin complex concentrate for reversal of factor Xa inhibitors in intracranial hemorrhage","volume":"35","author":"Ammar","year":"2021","journal-title":"Neurocrit Care"},{"key":"2025062323251232000_41.3.162.7","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1111\/jth.14838","article-title":"Evaluation of Andexanet Alfa and Four\u2010Factor prothrombin complex concentrate (4F\u2010Pcc) for reversal of Rivaroxaban\u2010 and Apixaban\u2010Associated intracranial hemorrhages","volume":"18","author":"Barra","year":"2020","journal-title":"J Thromb Haemost"},{"key":"2025062323251232000_41.3.162.8","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw210"},{"key":"2025062323251232000_41.3.162.9","unstructured":"National Institute for Health and Clinical Excellence (UK) . Andexanet Alfa for reversing anticoagulation form Apixaban or Rivaroxaban: technology appraisal guidance. 2021. Available: https:\/\/www.nice.org.uk\/guidance\/ta697\/resources\/andexanet\u2010alfa\u2010for\u2010reversing\u2010anticoagulation\u2010from\u2010apixaban\u2010or\u2010rivaroxaban\u2010pdf\u201082609445558725 [Accessed 8 Sep 2023]."},{"key":"2025062323251232000_41.3.162.10","unstructured":"ClinicalTrials.gov . Trial of Andexanet Alfa in Icrh patients receiving an oral Fxa inhibitor. n.d. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03661528"},{"key":"2025062323251232000_41.3.162.11","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.40145","article-title":"Evaluation of direct oral anticoagulant reversal agents in intracranial hemorrhage: a systematic review and meta-analysis","volume":"5","author":"Chaudhary","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2025062323251232000_41.3.162.12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-782060"},{"key":"2025062323251232000_41.3.162.13","doi-asserted-by":"crossref","DOI":"10.1186\/s40560-018-0303-y","article-title":"Safety of 4-factor prothrombin complex concentrate (4F-PCC) for emergent reversal of factor Xa inhibitors","volume":"6","author":"Tao","year":"2018","journal-title":"J Intensive Care"},{"key":"2025062323251232000_41.3.162.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1814051"},{"key":"2025062323251232000_41.3.162.15","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ajem.2022.02.029","article-title":"Andexanet Alfa versus four-factor prothrombin complex concentrate for the reversal of Apixaban- or Rivaroxaban-associated intracranial hemorrhages","volume":"55","author":"Pham","year":"2022","journal-title":"Am J Emerg Med"},{"key":"2025062323251232000_41.3.162.16","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2217\/fca-2020-0073","article-title":"Real-world management of oral factor Xa inhibitor-related bleeds with reversal or replacement agents including Andexanet Alfa and four-factor prothrombin complex concentrate: a multicenter study","volume":"17","author":"Coleman","year":"2021","journal-title":"Future Cardiol"}],"container-title":["Emergency Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/emermed-2023-213229","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T06:25:47Z","timestamp":1750746347000},"score":1,"resource":{"primary":{"URL":"https:\/\/emj.bmj.com\/lookup\/doi\/10.1136\/emermed-2023-213229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,24]]},"references-count":16,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,2,20]]},"published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1136\/emermed-2023-213229"],"URL":"https:\/\/doi.org\/10.1136\/emermed-2023-213229","relation":{},"ISSN":["1472-0205","1472-0213"],"issn-type":[{"value":"1472-0205","type":"print"},{"value":"1472-0213","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,24]]}}}